Sphingomyelin synthase 2 activity and liver steatosis an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 7, 2013, Pages 1513-1520

  Li, Yue ^a,b   Dong, Jibin ^b   Ding, Tingbo ^a,b   Kuo, Ming Shang ^d   Cao, Guoqing ^e   Jiang, Xian Cheng ^a,c   Li, Zhiqiang ^a,c  

^a SUNY Downstate Medical Center   (United States)

^b FUDAN UNIVERSITY   (China)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e Jiangsu Hengrui Medicine   (China)

Author keywords

CD36; Ceramide; Liver lipids; Liver steatosis; Peroxisome proliferator activated receptor 2; Sphingolipids; Sphingomyelin

Indexed keywords

CD36 ANTIGEN; CERAMIDE; FATTY ACID; FSP27 PROTEIN; MEMBRANE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN SYNTHASE 1; SPHINGOMYELIN SYNTHASE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FATTY ACID TRANSPORT; FATTY LIVER; HUMAN; HUMAN CELL; LIPOGENESIS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

CD36; CERAMIDE; LIVER LIPIDS; LIVER STEATOSIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Γ2; SPHINGOLIPIDS; SPHINGOMYELIN;

ANIMALS; ANTIGENS, CD36; CELL LINE, TUMOR; CERAMIDES; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FATTY LIVER; FEMALE; GENES, REPORTER; HUMANS; LIVER; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; MICE, TRANSGENIC; PHOSPHATIDYLCHOLINES; PPAR GAMMA; SPHINGOMYELINS; TIME FACTORS; TRANSFECTION; TRANSFERASES (OTHER SUBSTITUTED PHOSPHATE GROUPS);

EID: 84879102853     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301498     Document Type: Article

References (40)

1. Bikman BT, Summers SA. Sphingolipids and hepatic steatosis. Adv Exp Med Biol. 2011;721:87-97.
2. Liu J, Zhang H, Li Z, Hailemariam TK, Chakraborty M, Jiang K, Qiu D, Bui HH, Peake DA, Kuo MS, Wadgaonkar R, Cao G, Jiang XC. Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice. Arterioscler Thromb Vasc Biol. 2009;29:850-856.
3. Li Z, Fan Y, Liu J, Li Y, Huan C, Bui HH, Kuo MS, Park TS, Cao G, Jiang XC. Impact of sphingomyelin synthase 1 deficiency on sphingolipid metabolism and atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32:1577-1584.
4. Merrill AH Jr. Characterization of serine palmitoyltransferase activity in chinese hamster overy cells. Biochimica et biophysica acta. 1983;754:284-291.
5. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science. 1996;274:1855-1859.
6. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res. 2001;88:998-1003.
7. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol. 1998;18:1523-1533.
8. Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. Oncogene. 2003;22:7070-7077.
9. de Mello VD, Lankinen M, Schwab U, Kolehmainen M, Lehto S, Seppänen-Laakso T, Oresic M, Pulkkinen L, Uusitupa M, Erkkilä AT. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia. 2009;52:2612-2615.
10. Ichi I, Takashima Y, Adachi N, Nakahara K, Kamikawa C, Harada-Shiba M, Kojo S. Effects of dietary cholesterol on tissue ceramides and oxidation products of apolipoprotein B-100 in ApoE-deficient mice. Lipids. 2007;42:893-900.
11. Pohl J, Ring A, Korkmaz U, Ehehalt R, Stremmel W. FAT/CD36-mediated long-chain fatty acid uptake in adipocytes requires plasma membrane rafts. Mol Biol Cell. 2005;16:24-31.
12. Buqué X, Martínez MJ, Cano A, Miquilena-Colina ME, García-Monzón C, Aspichueta P, Ochoa B. A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. J Lipid Res. 2010;51:500-513.
13. Degrace P, Moindrot B, Mohamed I, Gresti J, Du ZY, Chardigny JM, Sébédio JL, Clouet P. Upregulation of liver VLDL receptor and FAT/CD36 expression in LDLR-/-apoB100/100 mice fed trans-10,cis-12 conjugated linoleic acid. J Lipid Res. 2006;47:2647-2655.
14. Nicholson AC, Hajjar DP. CD36, oxidized LDL and PPAR gamma: pathological interactions in macrophages and atherosclerosis. Vascul Pharmacol. 2004;41:139-146.
15. Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, Miyoshi S, Suzuki Y, Saito H, Kohgo Y, Okumura T. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun. 2005;336:215-222.
16. Tontonoz P, Hu E, Spiegelman BM. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev. 1995;5:571-576.
17. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-1234.
18. Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, Feingold KR. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology. 2000;141:4021-4031.
19. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without white fat: a transgenic mouse. Genes Dev. 1998;12:3168-3181.
20. Zhang YL, Hernandez-Ono A, Siri P, Weisberg S, Conlon D, Graham MJ, Crooke RM, Huang LS, Ginsberg HN. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem. 2006;281:37603-37615.
21. Li Z, Zhang H, Liu J, et al. Reducing plasma membrane sphingomyelin increases insulin sensitivity. Mol Cell Biol. 2011;31:4205-4218.
22. Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, Tu YH, Cook RF, Sargiacomo M. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol. 1994;126:111-126.
23. Müller G, Jung C, Wied S, Welte S, Jordan H, Frick W. Redistribution of glycolipid raft domain components induces insulin-mimetic signaling in rat adipocytes. Mol Cell Biol. 2001;21:4553-4567.
24. Gustavsson J, Parpal S, Karlsson M, Ramsing C, Thorn H, Borg M, Lindroth M, Peterson KH, Magnusson KE, Strâlfors P. Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J. 1999;13:1961-1971.
25. Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, Samad F. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab. 2009;297:E211-E224.
26. Bijl N, Sokolović M, Vrins C, Langeveld M, Moerland PD, Ottenhoff R, van Roomen CP, Claessen N, Boot RG, Aten J, Groen AK, Aerts JM, van Eijk M. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology. 2009;50:1431-1441.
27. Deevska GM, Rozenova KA, Giltiay NV, Chambers MA, White J, Boyanovsky BB, Wei J, Daugherty A, Smart EJ, Reid MB, Merrill AH Jr., Nikolova-Karakashian M. Acid sphingomyelinase deficiency prevents diet-induced hepatic triacylglycerol accumulation and hyperglycemia in mice. J Biol Chem. 2009;284:8359-8368.
28. Mitsutake S, Zama K, Yokota H, Yoshida T, Tanaka M, Mitsui M, Ikawa M, Okabe M, Tanaka Y, Yamashita T, Takemoto H, Okazaki T, Watanabe K, Igarashi Y. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes. J Biol Chem. 2011;286:28544- 28555.
29. Liu J, Huan C, Chakraborty M, Zhang H, Lu D, Kuo MS, Cao G, Jiang XC. Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. Circ Res. 2009;105:295-303.
30. Hailemariam TK, Huan C, Liu J, Li Z, Roman C, Kalbfeisch M, Bui HH, Peake DA, Kuo MS, Cao G, Wadgaonkar R, Jiang XC. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol. 2008;28:1519-1526.
31. Okumura T. Role of lipid droplet proteins in liver steatosis. J Physiol Biochem. 2011;67:629-636.
32. Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab. 2012;23:365-371.
33. Yetukuri L, Katajamaa M, Medina-Gomez G, Seppänen-Laakso T, Vidal-Puig A, Oresic M. Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol. 2007;1:12.
34. Kajita K, Mune T, Kanoh Y, Natsume Y, Ishizawa M, Kawai Y, Yasuda K, Sugiyama C, Ishizuka T. TNFalpha reduces the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) via the production of ceramide and activation of atypical PKC. Diabetes Res Clin Pract. 2004;66 suppl 1:S79-S83.
35. Xu F, Yang CC, Gomillion C, Burg KJ. Effect of ceramide on mesenchymal stem cell differentiation toward adipocytes. Appl Biochem Biotechnol. 2010;160:197-212.
36. Lee SY, Kim JR, Hu Y, Khan R, Kim SJ, Bharadwaj KG, Davidson MM, Choi CS, Shin KO, Lee YM, Park WJ, Park IS, Jiang XC, Goldberg IJ, Park TS. Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction. J Biol Chem. 2012;287:18429-18439.
37. Ables GP. Update on ppargamma and nonalcoholic fatty liver disease. PPAR Res. 2012;2012:912351.
38. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-812.
39. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995;83:813-819.
40. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol. 2004;20:455-480.